Form 4: Indaptus Therapeutics Director Hila Karah Granted 12,500 Stock Options

Indaptus Therapeutics, Inc. Director Hila Karah was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Summary

• Hila Karah, a Director of Indaptus Therapeutics, Inc. (INDP), was granted 12,500 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $0.33.
• The options will vest and become exercisable on June 10, 2026.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Hila Karah beneficially owns 12,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive and routine event, indicating continued alignment of management incentives with shareholder interests, which is generally viewed favorably.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The vesting schedule of the stock options on June 10, 2026, indicates a future milestone for the director's equity compensation, aligning their long-term commitment with the company's performance.

Management Comments

• The filing was signed by Hila Karah, the reporting person.

Industry Context

This transaction is a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, common for aligning executive and board incentives with shareholder value creation in growth-oriented companies like Indaptus Therapeutics.

Comparison to Industry Standards

• The grant of stock options to directors is a widely accepted practice across various industries, including biotechnology, as a form of non-cash compensation.
• While the specific number of options and exercise price are unique to this grant, the mechanism of equity-based incentives is consistent with compensation strategies at comparable companies aiming to retain talent and foster long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Hila Karah, a director of Indaptus Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for equity-based incentives within the company.

Next Steps

• The stock options will vest and become exercisable on June 10, 2026.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Hila Karah, Stock Option, Director, Equity Compensation, Beneficial Ownership, SEC Form 4, Insider Transaction